Imugene

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Retrieved on: 
Tuesday, January 23, 2024

Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.

Key Points: 
  • Under the terms of the agreement, Imugene obtains non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform.
  • In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
  • Imugene, which has offices in the United States and Australia, is focused on developing transformative cancer medicines to improve patients’ lives.
  • Imugene is MaxCyte’s 25th SPL overall, which generates pre-commercial milestone revenue, the vast majority of which includes post-commercial revenue.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, January 9, 2024

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.

Key Points: 
  • “We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
  • Precision will also receive $2.5 million within 12 months, as an equity investment in Precision’s common stock at 100% premium to the then 30-day VWAP prior to purchase.
  • Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP.
  • These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs.

RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Tuesday, November 14, 2023

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the third quarter ended September 30, 2023.
  • Financial Highlights for Third Quarter ended September 30, 2023:
    Cash Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million.
  • R&D Expenses: Research and development expenses were $1.6 million for the quarter ended September 30, 2023, compared to $0.8 million for the quarter ended September 30, 2022.
  • Net Loss: Net loss was $1.4 million for the quarter ended September 30, 2023, compared to net loss of $2.1 million for the quarter ended September 30, 2022.

RenovoRx to Present at the ROTH MKM Healthcare Opportunities Conference on October 12, 2023

Retrieved on: 
Monday, October 2, 2023

RenovoRx, Inc .

Key Points: 
  • RenovoRx, Inc .
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that CEO, Shaun Bagai, will present at the ROTH MKM Healthcare Opportunities Conference in New York on October 12, 2023.
  • Register here .
  • Moderated by Scott Henry, Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research at ROTH Capital Partners, LLC, will conduct a fireside chat with Mr. Bagai, who will discuss recent Company milestones, including the research collaboration with Imugene (ASX: IMU), and highlights from RenovoRx’s open label pivotal Phase III TIGeR- PaC study.

Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

Retrieved on: 
Wednesday, August 16, 2023

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based in vivo gene editing therapies, today announced completion of a strategic transaction with Imugene Limited (ASX: IMU) for global rights to Azercabtagene Zapreleucel (azer-cel), Precision’s lead allogeneic CAR T candidate, for cancer.
  • Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment.
  • The license also includes an option to develop up to three other cancer research programs in the future.
  • For each additional research program selected by Imugene, Precision is eligible for up to $145 million in milestone payments and tiered royalties on net sales.

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform

Retrieved on: 
Thursday, July 20, 2023

CALIFORNIA, USA, July 20, 2023 - (ACN Newswire) - RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

Key Points: 
  • CALIFORNIA, USA, July 20, 2023 - (ACN Newswire) - RenovoRx, Inc. ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
  • "We look forward to combining our proprietary TAMP platform with Imugene's CF33 oncolytic virus with the goal of optimizing clinical benefits for patients."
  • As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene's CF33 oncolytic virus technology with RenovoRx's TAMP therapy platform.
  • RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards - Life Sciences Edition 2020 for its TAMP therapy platform technology.

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform

Retrieved on: 
Thursday, July 20, 2023

("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

Key Points: 
  • ("RenovoRx") (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd ("Imugene") (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene's oncolytic virus therapy with RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
  • "We look forward to combining our proprietary TAMP platform with Imugene's CF33 oncolytic virus with the goal of optimizing clinical benefits for patients."
  • As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene's CF33 oncolytic virus technology with RenovoRx's TAMP therapy platform.
  • RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its TAMP therapy platform technology.

RenovoRx to Present at the 43rd Annual Canaccord Genuity Growth Conference

Retrieved on: 
Monday, July 31, 2023

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that its CEO Shaun Bagai will provide a corporate overview and update at the 43rd Annual Canaccord Genuity Growth Conference on Thursday, August 10, 2023 at 10:30 AM ET in Boston, MA.
  • The TIGeR-PaC study is evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer (LAPC).
  • Interim data demonstrates a 6-month overall survival benefit, 8-month delay in cancer progression, and 65% reduction in adverse effects over systemic (intravenous) chemotherapy.
  • To schedule a one-on-one investor meeting with RenovoRx’s management team, please contact a conference representative or KCSA Strategic Communications at [email protected] .

RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP™) Platform

Retrieved on: 
Thursday, July 20, 2023

(“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (“Imugene”) (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

Key Points: 
  • (“RenovoRx”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd (“Imugene”) (ASX: IMU), a clinical-stage immuno-oncology company, today announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.
  • “We believe the synergy between RenovoRx’s trans-arterial drug delivery system and our CF33 oncolytic virus platform has the potential to facilitate treatment of difficult-to-access cancers and help patients,” said Leslie Chong, Managing Director & Chief Executive Officer of Imugene.
  • “We look forward to combining our proprietary TAMP platform with Imugene’s CF33 oncolytic virus with the goal of optimizing clinical benefits for patients.”
    As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.
  • RenovoRx won the Drug Delivery Technology category of the Fierce Innovation Awards – Life Sciences Edition 2020 for its TAMP therapy platform technology.

Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting

Retrieved on: 
Thursday, November 10, 2022

One of the fields unanswered questions is whether treatment-nave allogeneic CAR T cells are superior to cancer patient-derived T cells for product manufacturing to improve overall responses against solid tumors.

Key Points: 
  • One of the fields unanswered questions is whether treatment-nave allogeneic CAR T cells are superior to cancer patient-derived T cells for product manufacturing to improve overall responses against solid tumors.
  • This combination strategy was evaluated using two allogeneic CAR T cell products generated from peripheral blood mononuclear cells (PBMC) and placental T cells, respectively.
  • CYCART-19 T cells induced potent cytolytic activity against solid tumor cells infected with onCARlytics.
  • Interestingly, while we observed comparable anti-tumor activity between PBMC-derived CD19-CAR T cells and CYCART-19, differences in cytokine secretion were detected.